Ready to start planning your care? Call us at $\frac{800-525-2225}{100}$ to make an appointment.



Memorial Sloan Kettering Cancer Center

Find ane War Appeton on Gancer Specialist

Refer a Patient

ABOUT US

Our mission, vision & core values

Leadership

History

Equality, diversity & inclusion

Annual report

Give to MSK

Melanoma

Clinical Trials of New Immunotherapeutic and Targeted Therapeutic Agents

View all

♥ Dr. Postow's Office Information

⊕

Languages: English

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.

Call 646-497-9067

Make an appointment

About Me

Michael A. Postow

•

What I Do at MSK

- Chief, Melanoma Service
- Co-Director, Melanoma Disease Management Team

Get To Know Me

I am the Chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center (MSK), where my practice is devoted solely to the care of people with <u>melanoma</u>. It is my privilege to lead an outstanding group of medical oncologists, nurses, and researchers with world-leading expertise in the treatment and management of melanoma.

Many FDA-approved therapies for patients with melanoma were developed by our team, including the combination of nivolumab (Opdivo®) and ipilimumab (Yervoy®). The regimen has since been recognized as a <u>major scientific advance in melanoma</u> by The American Society of Clinical Oncology.

Read more + My Role at MSK

A melanoma oncologist is a cancer doctor with special training in melanoma. This includes superficial spreading, nodular, lentigo maligna, and acral lentiginous melanomas, as well as eye, mucosal, and rare skin melanomas.

Areas of Expertise

My Specialties

Melanoma

Clinical Trials of New Immunotherapeutic and Targeted Therapeutic Agents

Education & Honors

Education

MD, New York University School of Medicine

Residencies

Internal Medicine - Harvard University/Brigham and Women's Hospital

Awards and Honors

Solid Tumor Teacher of the Year Award, Memorial Sloan Kettering Cancer Center (2022, 2019) Best Teaching Service Award (Melanoma, 2022) 40 Under 40 in Cancer Award, The Lynx Group (2020) Julia Zelmanovich Young Alumni Award, New York University Grossman School of Medicine

Fellowships

Medical Oncology - Memorial Sloan Kettering Cancer Center Medical Oncology - Weill Cornell Medical College

Board Certifications

Internal Medicine Medical Oncology

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

•

Enter your insurance provider

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our <u>financial assistance</u> programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Make an Appointment



New Patients

Scheduling an appointment is easy. Click or call 646-497-9067— we're available Monday through Friday, 8 a.m. to 6 p.m. (Eastern time)

Make an Appointment

Current Patients

Request an appointment by logging on to MyMSK or calling your doctor's office. If you aren't registered for MyMSK, call 646-227-2593 for your Enrollment ID.

Contact and Location

Dr. Postow sees patients at one location.

Office Phone

<u>646-888-4589</u>

Location

📍 New York, NY

Rockefeller Outpatient Pavilion 160 East 53rd Street New York, NY 10022 Get Directions

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

<u>See all Melanoma Service doctors</u> →

Clinical Trials

Clinical Trials Investigated by Dr. Postow

A Phase 3 Study of the Personalized V940 Cancer Vaccine Plus Pembrolizumab Immunotherapy After Surgery in People With Melanoma

CD8+ T Cell Imaging During Immunotherapy Before Surgery in People with Melanoma

Clinical Trials Co-Investigated by Dr. Postow

A Phase 2 Study of IO102/IO103, Nivolumab, and Relatlimab Immunotherapy in People With Melanoma

A Phase I/IIA Study of LNS8801 with and without Pembrolizumab Immunotherapy in People with Advanced Melanoma

Read more



Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Postow MA, Goldman DA, Shoushtari AN, Betof Warner A, Callahan MK, Momtaz P, Smithy JW, Naito E, Cugliari MK, Raber V, Eton O, Nair SG, Panageas KS, Wolchok JD, Chapman PB. Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study). J Clin Oncol. 2022 Apr 1;40(10):1059-1067. doi: 10.1200/JCO.21.01570. Epub 2021 Dec 20. PMID: 34928709; PMCID: PMC8966970.

Postow MA, Knox SJ, Goldman DA, Elhanati Y, Mavinkurve V, Wong P, Halpenny D, Reddy SK, Vado K, McCabe D, Ramirez KA, Macri M, Schwarzenberger P, Ricciardi T, Ryan A, Venhaus R, Momtaz P, Shoushtari AN, Callahan MK, Chapman PB, Wolchok JD, Subrahmanyam PB, Maecker HT, Panageas KS, Barker CA. A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma. Clin Cancer Res. 2020 Jul 1;26(13):3193-3201. doi: 10.1158/1078-0432.CCR-19-3936. Epub 2020 Mar 23. PMID: 32205463; PMCID: PMC7959513.

Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018 Jan 11;378(2):158-168. doi: 10.1056/NEJMra1703481. PMID: 29320654.

Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS. <u>Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.</u> N Engl J Med. 2015 May 21;372(21):2006-17. doi: 10.

Pocket Oncology. Drilon AE, Postow MA eds. Philadelphia: Lippincott Williams & Wilkins; 2014.

Publications on PubMed

Visit PubMed for a full listing of Dr. Postow's journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

<u>See all on PubMed</u> →

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report ("disclose") the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Michael A. Postow discloses the following relationships and financial interests:

Bristol-Myers Squibb Professional Services and Activities Cancer Expert Now, Inc. Professional Services and Activities Chugai Pharmaceuticals Professional Services and Activities Intellisphere, LLC Professional Services and Activities MJH Associates Professional Services and Activities Marck & Co Inc.

Nektar Therapeutics Professional Services and Activities Pfizer, Inc. Professional Services and Activities Physicians' Education Resource Professional Services and Activities

Professional Services and Activities

UptoDate Intellectual Property Rights WebMD Professional Services and Activities

If you're a patient at MSK and would like more information about your doctor's external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies <u>here</u>. For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at <u>ecoi@mskcc.org</u>.

View all disclosures

Connect	
Contact us	
Locations	
APPOINTMENTS	
<u>800-525-2225</u>	
About MSK	
About us	
Careers	
Giving	
Cancer Care	
Adult concertures	
Adult cancer types	
Child & teen cancer types	
Integrative medicine	

Nutrition & cancer

Find a doctor

Research & Education

Sloan Kettering Institute

Gerstner Sloan Kettering Graduate School

Graduate medical education

MSK Library

Communication preferences Cookie preferences Legal disclaimer Accessibility statement Privacy policy Price transparency Public notices © 2024 Memorial Sloan Kettering Cancer Center